[2-(1-benzyl-1H-indazol-3-yloxy)-ethyl]-dimethyl-amine | 1040-07-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: [2-(1-benzyl-1H-indazol-3-yloxy)-ethyl]-dimethyl-amine
• 英文别名: 1-Benzyl-3-(β-dimethylaminoethoxy)-1H-indazole；2-(1-benzylindazol-3-yl)oxy-N,N-dimethylethanamine
• CAS: 1040-07-9
• 化学式: C₁₈H₂₁N₃O
• 分子量: 295.384
• InChiKey: YPCKAUKDLJKZNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二甲氨基氯乙烷盐酸 、 1-苄基-3-羟基-1H-吲唑 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以66%的产率得到[2-(1-benzyl-1H-indazol-3-yloxy)-ethyl]-dimethyl-amine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Pyrazoles and Indazoles as Activators of the Nitric Oxide Receptor, Soluble Guanylate Cyclase

  摘要：

  Database searching and compound screening identified 1-benzyl-3-(3-dimethylaminopropyloxy)-indazole (benzydamine, 3) as a potent activator of the nitric oxide receptor, soluble guanylate cyclase. A comprehensive structure-activity relationship study surrounding 3 clearly showed that the indazole C-3 dimethylaminopropyloxy substituent was critical for enzyme activity. However replacement of the indazole ring of 3 by appropriately substituted pyrazoles maintained enzyme activity. Compounds were evaluated for inhibition of platelet aggregation and showed a general lipophilicity requirement. Aryl-substituted pyrazoles 32, 34, and 43 demonstrated potent activation of soluble guanylate cyclase and potent inhibition of platelet aggregation. Pharmacokinetic studies in rats showed that compound 32 exhibits modest oral bioavailability (12%). Furthermore 32 has an excellent selectivity profile notably showing no significant inhibition of phosphodiesterases or nitric oxide synthases.

  DOI：

  10.1021/jm001034k

文献信息

• Methods and compositions of treating a flaviviridae family viral infection
  申请人：Einav Shirit

  公开号：US20100015093A1

  公开（公告）日：2010-01-21

  Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

  简要概述，本公开的实施例包括化合物、药物组合物、治疗感染黄病毒科病毒的宿主的方法、抑制宿主中HCV复制的方法、抑制NS4B多肽与HCV负链RNA的3′UTR结合的方法、治疗宿主肝纤维化的方法等。
• METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION
  申请人：Glenn Jeffrey S.

  公开号：US20120148534A1

  公开（公告）日：2012-06-14

  Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

  简单地说，本公开的实施例包括化合物、药物组合物、治疗感染黄病毒科病毒的宿主的方法、抑制宿主中HCV复制的方法、抑制NS4B多肽与HCV负链RNA的3'UTR结合的方法、治疗宿主肝纤维化的方法等。
• US8940730B2
  申请人：——

  公开号：US8940730B2

  公开（公告）日：2015-01-27
• US9149463B2
  申请人：——

  公开号：US9149463B2

  公开（公告）日：2015-10-06
• [EN] METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION<br/>[FR] MÉTHODES ET COMPOSITIONS POUR TRAITER L'INFECTION PAR UN VIRUS DE LA FAMILLE DES FLAVIVIRIDAE
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2010107742A2

  公开（公告）日：2010-09-23

  Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3'UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.